Share Name Share Symbol Market Type Share ISIN Share Description
Circassia Pharmaceuticals Plc LSE:CIR London Ordinary Share GB00BJVD3B28 ORD 0.08P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.80p -3.04% 25.50p 924,716 16:10:45
Bid Price Offer Price High Price Low Price Open Price
25.50p 25.80p 26.40p 25.30p 26.10p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 48.30 -55.80 -34.00 95.6

Circassia Pharmaceuticals (CIR) Latest News

More Circassia Pharmaceuticals News
Circassia Pharmaceuticals Takeover Rumours

Circassia Pharmaceuticals (CIR) Share Charts

1 Year Circassia Pharmaceuticals Chart

1 Year Circassia Pharmaceuticals Chart

1 Month Circassia Pharmaceuticals Chart

1 Month Circassia Pharmaceuticals Chart

Intraday Circassia Pharmaceuticals Chart

Intraday Circassia Pharmaceuticals Chart

Circassia Pharmaceuticals (CIR) Discussions and Chat

Circassia Pharmaceuticals Forums and Chat

Date Time Title Posts
25/5/201922:47Circassia Pharma PLC 236
20/10/200610:49Capricorn Resouces PLC - 50% premium in half a day811
10/2/200515:35100 % on no time12

Add a New Thread

Circassia Pharmaceuticals (CIR) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Circassia Pharmaceuticals trades in real-time

Circassia Pharmaceuticals (CIR) Top Chat Posts

Circassia Pharmaceuticals Daily Update: Circassia Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker CIR. The last closing price for Circassia Pharmaceuticals was 26.30p.
Circassia Pharmaceuticals Plc has a 4 week average price of 24.90p and a 12 week average price of 24.90p.
The 1 year high share price is 97.90p while the 1 year low share price is currently 24.90p.
There are currently 374,870,649 shares in issue and the average daily traded volume is 512,673 shares. The market capitalisation of Circassia Pharmaceuticals Plc is £95,592,015.50.
the abbot: I am confident the price will rise here now the shorter is reducing, add to that the 2 FDA approvals and the general synopsis of the company and I think any purchases made recently are going to shine for their investor owners. However, what I am not happy about, and have made my views blatently clear to the company Directors, is their own seeming disregard for the protection of their share price and the one central aim which should be to return shareholder value. The same shareholders that support the company when required. I find it amazing that the Directors have not placed their hands in their pockets and purchased any shares, maybe its because they have been gifted so many that they don't feel the need, although the last non exec immediately sold his gifted options at a price of £0.0008 (i.e. an outlay of just £62) for a total of £69,060.25. How can they not see value at 25p a share. I am always angered at companys that like to award themselves options at ridiculously low prices and then think it is ok to exercise those options for pence and sell for thousands, when they have delivered zero shareholder value. At the AGM this year I would vote against the renumneration and against the ability to use the issuing of shares to pay their contractors. These Directors need to start delivering. Please remember before somone points out 'why am I invested' it is not for the love of the directors or how the company is run, it is purely transactional, I believe the shareprice will rise and I think the drugs and FDA approvals gives the company a huge advantage over its competitors in a very large field of ailment this being COPD.
turvart: Do CIr have any exposure to UK sales?
badger60: the abbotYep..... unfortunately these days many promising small caps are very poorly marketed and/or become the object of manipulation by nearly everybody (understandably) becomes a trader, and I'm not too good at that.The big money for me is (choosing the right stock) made by being patient. On balance I have done well over the years, but also taken a few chunky hits along the way. Hemogenyx imo is potentially a serious multibagger, but it has been unloved, overlooked and very badly handled by the market since it came in October 2017, and like CIR much of the the embedded value is in no way reflected in the share price or market cap. ......but that's what no pain, no gain is all about.Good luck here....ttfn.
gersemi: 6 hours ago Circassia slashes net cash outflow By Mark Robinson Drug developers require a steady stream of positive clinical updates to underpin market valuations. Circassia Pharmaceuticals (CIE) provided shareholders with precisely that a month ahead of these full-year figures when it revealed that US regulators had given the green light for two of its chronic obstructive pulmonary disease (COPD) treatments. It is too early to say whether the news has arrested the share price decline of the previous 12-months, but given that very few UK-sponsored drugs have been approved in the US in the past few years, so the news - particularly in relation to the Duaklir drug - would not have gone unnoticed amongst the sector heavyweights. The drugs are complementary in that patients using its existing COPD treatment Tudorza (which got the go-ahead for the inclusion of new clinical data on its label) can move on to Duaklir if their condition deteriorates without needing to change their inhaler device. Bloomberg consensus gives revenues of £64.5m for the December 2019 year-end, with an accompanying adjusted earnings loss of 7.6p a share, before £84.8m and a 5.2p loss in the following year. CIRCASSIA PHARMACEUTICALS (CIR) ORD PRICE: 32p MARKET VALUE: £ 120m TOUCH: 31.2-32p 12-MONTH HIGH: 98p LOW: 25p DIVIDEND YIELD: NIL PE RATIO: NA NET ASSET VALUE: 34p* NET CASH: £40.7m Year to 31 Dec Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p) 2014 nil -44.0 -21 nil 2015 10.8 -62.8 -20 nil 2016 23.1 -38.8 -48 nil 2017 (restated) 46.3 -74.2 -19 nil 2018 48.3 -55.8 -14 nil % change +4 - - - Ex-div: - Payment: - *Includes intangible assets of £231m, or 61.5p a share. IC View Duaklir was initially approved in the European Union five years ago, but the US launch in the second half of 2019 is highly significant given the potential up-scale. With a new revenue stream in prospect, 2018 may come to be seen as a watershed for the company. Though the net cash-outflow fell by two-thirds to £18.8m, the continued backing by AstraZeneca (AZN), which boosted its holding to 19.9 per cent midway through last year, has been crucial. However, given the lowly free-float, shareholders may struggle to buy into the US growth story. Hold. Last IC view: Hold, 34p, 01 Apr 2019 end
the abbot: I expect we have a strong potential for a short squeeze on Wednesday, I just listened to the Proactive interview and you can clearly hear that Steve Harris is excited about the results, these will additionally be marketed to the investment community with the appropriate forward looking statements relating to the newly achieved FDA approvals. I am quite surprised that at this price the buys are not larger, however if a short is going to close, not sure how easy it is going to be to buy shares back in the market to replace the loaned ones, I think they will have to accept that the profits they see today on paper, are not going to be what they walk away with, any buying and the price will motor. Hate the term under the radar particularly with the recent broker reviews, but heh I'm fine with this, looking at the past performance and share price I am very happy to be starting my investment here at 30p a share.
aspringo: Shouldn't average down but have done a Woodford. My buys show as sells, just for info.Fingers crossed this isn't the basket case the share price reflects.
paleje: Tempus in today's Times says its a buy. When Circassia came to the market in 2014 at 310p a share, it was seen as the owner of a promising but unproven treatment for allergies, including hay fever. En route the company paid £239 million for a couple of companies making treatments for asthma and pulmonary disease, raising fresh funds at 288p a share. The first widescale trials of that allergy treatment for people allergic to cats have been an unmitigated disaster. Put simply, sufferers given the treatment did well but so did those given a placebo. This is frankly baffling. Circassia is giving up trials of the same treatment for sufferers of hay fever and those allergic to ragweed, though two others are sufficiently well advanced that there is no point in abandoning them. The conclusion of these may give an idea why the feline trials went so badly and whether the treatment has any value whatsoever. This leaves the company with those asthma products, several of which are on the market. If the study was baffling, the market’s response was equally so. Circassia shares lost two thirds of their value, falling 179¼p to 91p. This gives it a market capitalisation of £257 million. Tot up the cost of those acquisitions and the cash in the bank and you get to £379 million. This suggests that the fall in the price is wildly overdone, assuming those businesses bought have the value ascribed to them, with the original allergy treatment assigned no value whatsoever. Any biotech company is always going to be speculative, but this looks a good gamble. MY ADVICE Buy WHY Risky, but the share price fall looks overdone
battlebus2: I'd be a buyer philander, when the cat allergy comes to market the share price will be treble todays imv.
miamigo: thecynical That's because last Feb they released this RNS, which subsequently came to nothing, but did, as you say, cause a flurry of interest: Capricorn Resources PLC 07 February 2005 Capricorn Resources plc ('the Company') Statement regarding a possible acquisition. The Company notes the recent increase in its share price. The Company is in discussions that may or may not lead to an acquisition that would constitute a substantial and a related party transaction, but not a reverse transaction under the AIM Rules. A further announcement will be made in due course. This information is provided by RNS The company news service from the London Stock Exchange
miamigo: This was posted on the WNL board. Looks like Phillipe is pretty busy at the moment. Not sure if any of these goings on will have any effect on CIR, but worth a read nontheless. Drilling for Oil? Start Prospecting in London: Matthew Lynn March 16 (Bloomberg) -- Where is the best place in the world to look for oil? Under the Indian Ocean? In some of the remote regions of Africa? Down around some of those countries with long, tricky-to- spell names that used to be part of the Soviet Union? No. The best place to prospect for oil right now is London. The London stock market is going through a speculative frenzy over oil exploration stocks. Investors are piling into stocks based on little more than rumors and hope. Shares are being sold on the back of the purported expertise of developers, not business plans. Is this just another dot-com style bubble? Or is there a real investment opportunity underneath the hoopla and the hype? For a flavor of oil mania 2005, here are two examples. On March 14, Afren Plc., a new oil and gas company, listed its shares on the London exchange at 20 pence each. By lunchtime, they had jumped to more than 56 pence, almost tripling in just a few hours. The London-based company raised 8 million pounds ($15.3 million) in its initial public offering. Afren has a starry pedigree. The directors include Rilwanu Lukman, a former president and secretary-general of OPEC. Another director, Egbert Imomoh, used to run the Nigerian operations of Royal Dutch/Shell Group. The company clearly has people on its team who know a lot about oil. White Nile Investors in White Nile, however, might regard those gains as relatively paltry. Last month, the company soared in value. White Nile is an exploration company set up by the former England cricket star Phil Edmonds. Listed on the London market at the start of February, the shares increased more than 11-fold in a week before being suspended. The Financial Times reported that the U.K. Financial Services Authority was investigating the price surge, which came just before an announcement that White Nile had obtained a stake in an oil field in Sudan. The shares are still suspended. There have been plenty of other spectacular gains. Centurion Energy International Inc., which develops oil assets in Tunisia, has seen its share price rise from just 52 pence in 2003 to a high of 780 pence last month. Desire Petroleum Plc has seen its shares soar from 22 pence last year to a peak of 67 pence this year, before falling back slightly. In total, 24 new oil exploration and production companies have been listed in London in the last 12 months, according to research by Al Stanton, an analyst with Bridgewell Securities Ltd in London. Another Prospectus ``Every day there is a thump on the door, and it's another oil company prospectus landing on the doormat,'' said Stanton in a telephone interview. ``Share prices are being pushed up very quickly, with what I suspect are thin volumes and a lot of trading from private investors. The man in the street could well get burned.'' The oil exploration frenzy is starting to show some spooky similarities to the dot-com bubble of five years ago. Take companies such as Afren and White Nile. They don't actually own any oil in the ground yet. Afren has an agreement to take part in a field in Nigeria. The rest of the money raised from investors will be used make acquisitions. Likewise White Nile. Again, no actual oil. At least not yet. According to a company statement, it was created ``to identify and acquire projects in the natural resources sector with particular emphasis on oil projects within Africa.'' Emphasis on Presentation While oil exploration by its nature always has been somewhat of a guessing game and companies jumping into that world may go on to great things, many of the new companies seem to be as much about presentation as future production. There are few better illustrations of that than FirstAfrica Oil Plc. It actually used to be a public relations business called Financial Development Corporation Plc before a reverse takeover at the start of this year. It's now in the oil exploration industry (and had been rewarded with a tripling of its share price). The prospects for small, nimble companies that are good at finding oil haven't looked better in years. The demand for oil has been rising strongly during the last two years, and so has the price. The oil giants need to replenish their reserves. Unrealistic Expectations It's not necessarily a bad thing that some oil companies are being floated on the backs of personalities. The oil industry depends on contacts as much as anything else. The more difficult the territory, the more important it is to know the right people. That may well be a crucial factor for success. The trouble is, a genuine investment story is being over- hyped, just as it was in the technology bubble. The market is channeling investment into an industry that needs it. Yet it is also creating unrealistic expectations and a playground for speculators. Very few of the technology companies that surfaced during that bubble actually went on to make any money, and the same will almost certainly be true of London's new wave of oil companies. To contact the writer of this column: Matthew Lynn in London at
Circassia Pharmaceuticals share price data is direct from the London Stock Exchange
Your Recent History
Circassia ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190526 00:04:22